Developmental trends in targeted radionuclide therapy: Biological aspects

Targeted Radionuclide Tumor Therapy: Biological Aspects

Volumn , Issue , 2008, Pages 387-397

  Stigbrand, Torgny ^a   Carlsson, Jörgen ^b   Adams, Gregory P ^c  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864055110     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-8696-0_21     Document Type: Chapter

References (22)

1. Goldenberg DM, Sharkey RM (2006) Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 50(4):248-64. Review.
2. De Nardo SJ, De Nardo GL (2006) Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 66(2 Suppl):S89-95. Review.
3. Wong JY (2006) Systemic targeted radionuclide therapy: potential new areas. Int J Radiat Oncol Biol Phys 66(2 Suppl):S74-82. Review.
4. Oyen WJ, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, Brans B (2007) Targeted therapy in nuclear medicine - current status and future prospects. Ann Oncol 18(11):1782-92. Review.
5. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ (2007) Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46(6):723-34. Review.
6. Witzig TE (2006) Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol 19(4):655-68. Review.
7. Murray D, McEwan AJ (2007) Radiobiology of systemic radiation therapy. Cancer Biother Radiopharm 22(1):1-23.
8. Hall EJ, Giaccia AJ (2006) Radiobiology for the radiologist. Chapter 22. Lippincott Williams & Wilkins, Philadelphia, PA (ISBN 0-7817-4151-3).
9. Tolmachev V, Carlsson J, Lundqvist H (2004) A limiting factor for the progress of radionuclide based cancer diagnostics and therapy; availability of suitable radionuclides. Acta Oncologica 43(3):264-75.
10. Sundberg AL, Almquist Y, Tolmachev V, Gedda L, Orlova A, Blomquist E, Carlsson J (2003) Combined effect of gefitinib ("Iressa", ZD1839) and targeted radiotherapy with 11At-EGF; Experimental therapy studies in vitro. Eur J Nucl Med 30:1348-1356.
11. Nordberg E, Steffen AC, Persson M, Sundberg AL, Carlsson J, Glimelius B (2005) Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor. Eur J Nucl Med Mol Imaging 32(7):771-7.
12. Pecorino L (2005) Molecular biology of cancer. Mechanisms, targets and therapeutics. Oxford University Press, Oxford (ISBN 0-19-926472-4).
13. McGill MA, McGlade CJ (2004) Cellular signaling. In: The basic science of oncology (editors: Tannock IF, Hill RP, Bristow RC and Harrington L). Chapter 8. McGraw-Hill Medical Publishing Division, New York, pp. 142-66 (ISBN-13:978-0-07-138774-3).
14. Bublil EM, Yarden Y (2007) The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19(2):124-34. Review.
15. Bonner JA, Harari PM, Giralt J, et al. (2006) Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. NEJM 354:567-78.
16. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23(9):1147-57. Review.
17. Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP (2008) Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res 14:875-82.
18. Heldin C-H, Rubin K, Pietras K, Östman A (2004) High interstitial fluid pressure - an obstacle in cancer therapy. Nature Rev Cancer 4:806-13.
19. Martensson L, Nilsson R, Ohlsson T, Sjogren HO, Strand SE, Tennvall J (2007) Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion. J Nucl Med 48:269-76.
20. Erlandsson A, Eriksson D, Johansson L, Riklund K, Stigbrand T, Sundstrom BE (2006) In vivo clearing of idiotypic antibodies with antiidiotypic antibodies and their derivatives. Mol Immunol 43:599-606.
21. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24:823-34.
22. Goldenberg DM, Chatal JF, Barbet J, Boerman O, Sharkey RM (2007) Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2:19-31.